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ABSTRACT
Background Funding and resources for low prevalent 
neurodegenerative disorders such as amyotrophic 
lateral sclerosis (ALs) are limited, and optimising their 
use is vital for eficient drug development. In this study, 
we review the design assumptions for pivotal ALs 
clinical trials with time-to-event endpoints and provide 
optimised settings for future trials.
Methods We extracted design settings from 13 
completed placebo-controlled trials. Optimal assumptions 
were estimated using parametric survival models in 
individual participant data (n=4991). Designs were 
compared in terms of sample size, trial duration, drug 
use and costs.
Results Previous trials overestimated the hazard rate by 
18.9% (95% cI 3.4% to 34.5%, p=0.021). The median 
expected hR was 0.56 (range 0.33–0.66). Additionally, 
we found evidence for an increasing mean hazard rate 
over time (Weibull shape parameter of 2.03, 95% cI 
1.93 to 2.15, p<0.001), which affects the design and 
planning of future clinical trials. Incorporating accrual 
time and assuming an increasing hazard rate at the 
design stage reduced sample size by 33.2% (95% cI 
27.9 to 39.4), trial duration by 17.4% (95% cI 11.6 
to 23.3), drug use by 14.3% (95% cI 9.6 to 19.0) and 
follow-up costs by 21.2% (95% cI 15.6 to 26.8).
Conclusions Implementing distributional knowledge 
and incorporating accrual at the design stage could 
achieve large gains in the eficiency of ALs clinical trials 
with time-to-event endpoints. We provide an open-
source platform that helps investigators to make more 
accurate sample size calculations and optimise the use of 
their available resources.
INTRODUCTION
The extensive clinical heterogeneity of patients with 
low prevalent neurodegenerative disorders, such as 
amyotrophic lateral sclerosis (ALS), complicates the 
design of clinical trials.13 Disease heterogeneity 
inflates the variability in endpoints and, subse-
quently, the number of patients to demonstrate 
therapeutic efficacy.1 3 In addition, large treatment 
effects in these disorders are unlikely, forcing inves-
tigators to search for subtle proofs of efficacy.4 
Relatively large sample sizes are, therefore, needed 
in a rare disorder, which stresses the importance of 
optimising clinical trial design.
ALS is characterised by a progressive loss of 
motor neurons, leading to muscle weakness and, 
ultimately, death due to respiratory failure within 
35 years.5 6 As the life expectancy of patients with 
ALS is significantly reduced, survival time is one 
of the preferred outcomes for assessing treatment 
efficacy in pivotal ALS clinical trials.79 Although 
survival time could be influenced by interven-
tions such as gastrostomy or respiratory support 
and may not be optimal to detect early signals for 
efficacy,1 showing treatment benefit in terms of an 
increased life expectancy leaves little doubt about 
a drugs therapeutic potential. In contrast, treat-
ment benefits based solely on endpoints evaluating 
physical functioning (eg, Edaravone),10 could be 
deemed too marginal to warrant drug approval 
or to stop a trial during interim analyses.1114 
Combining survival time with other endpoints (eg, 
daily functioning, muscle strength or lung func-
tion) can considerably increase the efficiency of 
clinical trials.15 Measuring survival time in clinical 
trials for ALS is, therefore, indispensable and opti-
mising trial design for time-to-events endpoints (ie, 
survival time) may improve the overall efficiency of 
pivotal ALS clinical trials.
Trial design for time-to-event endpoints, and 
in particular sample size calculation, is, however, 
complex and depends on an array of assump-
tions. For example, the number of events (eg, 
deaths) during follow-up depends, among other 
things, on the hazard rate, accrual rate, dropout 
rate and expected treatment effect.1618 Each of 
these variables has its own inherent assumptions, 
and mis-specification of a single variable could 
negatively affect statistical power or unnecessarily 
expose patients to inferior treatment regimes.17
It has proved difficult to define evidence-based 
guidance for ALS trial design, which drives current 
pivotal ALS trials to use arbitrary and simplified 
assumptions. In this study, we evaluate the basic 
components of ALS trial design for time-to-event 
endpoints and provide optimised settings for future 
trials. We then introduce an open-access, web-based 
platform that assists investigators to implement and 
standardise optimal clinical trial methodology for 
ALS; a framework that could easily be extended to 
other fields with time-to-event endpoints.
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METHODS
A three-step approach was used to develop a framework for ALS 
clinical trials with time-to-event endpoints. First, we searched 
the literature for ALS clinical trials to compose a list of histor-
ical assumptions. We then obtained individual trial participant 
data to (1) obtain real-world estimates and (2) evaluate histor-
ical design settings. Finally, we validated designs and sample size 
calculations by means of simulation and incorporated the results 
in a web-based platform.
Literature search and data extraction
The systematic literature search and selection of studies has been 
described in more detail elsewhere.19 In short, all placebo-con-
trolled trials evaluating the efficacy of a single pharmaceutical 
agent, published in the period 20002018 and having survival 
as (co)-primary endpoint, were enrolled in this study. From each 
trial, we extracted the sample size, accrual time (date last enrolled 
patient  date first enrolled patient), minimum follow-up period, 
predicted probability of survival in the placebo arm, hypothe-
sised treatment effect (ie, HR), alpha (type I error), power (1 
 type II error) and the definition of an event. A plot digitalizer 
was then used to extract the observed survival probability from 
the published Kaplan-Meier curves.
Individual participant data
The Pooled Resource Open-Access ALS Clinical Trials (PRO-
ACT) database (version December 2015) was used as primary 
database to obtain real-world estimates of survival patterns 
among patients with ALS.20 PRO-ACT contains data for 10 731 
individuals from 23 trials performed over the past 20 years, is 
IRB-approved and uses solely anonymised data. Patients provided 
their consent to participate during the individual trials. For each 
PRO-ACT individual, we reconstructed their demographic, 
follow-up and survival data; if no survival data were available, 
patients were censored after their last known follow-up visit. 
We excluded participants without any follow-up time. The final 
dataset contained complete survival data from 3497 patients. In 
order to validate survival patterns, four external datasets that 
were not part of PRO-ACT were included from the following 
trials: Creatine (n=175),21 Valproic acid (n=163),22 LiCALS 
(n=214)23 and EMPOWER (n=942).24
Measures of effect
In order to evaluate how different design settings affect trial 
efficiency, we defined four measures of efficiency: (1) sample 
size, (2) trial duration, (3) drug usage and (4) follow-up costs. 
Trial duration was defined as the sum of the accrual period and 
the minimum follow-up duration (ie, date last follow-up  date 
enrolment first patient). Drug usage was defined as the sum of all 
follow-up time (in days) in the treatment arm. Costs of follow-up 
were calculated per patient based on the following hypothet-
ical scenario: screening and start-up fee $1500; monthly visits 
(eg, questionnaires and safety lab) $250; bimonthly visits (eg, 
additional muscle and lung function testing) $750 and biannual 
visits (eg, additional visit to neurologist) $1000. As an example: 
a patient who is followed up for 10.3 months would have 
one screening session, two biannual visits (M0 and M6), four 
bimonthly visits (M2, M4, M8 and M10) and five monthly visits 
(M1, M3, M5, M7 and M9), resulting in a total costs of $7750.
Statistical analysis
For all survival analyses, we used a two-sided log-rank test to 
compare the Kaplan-Meier curves of the placebo and active 
treatment arms. The number of events drives the statistical 
power of the log-rank test and is, therefore, the primary esti-
mate in sample size calculations. The number of events occurring 
during follow-up depends on a variety of variables; the primary 
determinants are the hazard rate, the total follow-up time and 
sample size. The hazard rate is a decisive design setting that 
heavily affects sample size calculations. In the case of a survival 
endpoint, where the event is death, the hazard rate can be inter-
preted as the instantaneous risk of dying.
In order to obtain insight into the underlying hazard rates in 
ALS clinical trials, we used parametric survival models following 
a Weibull distribution. The Weibull distribution allows time-
varying hazard rates (eg, the risk of dying is different at the start 
from that at the end of the trial), whereas the exponential distri-
bution assumes a constant hazard rate over time. The exponen-
tial distribution is a special case of the Weibull distribution with 
the shape parameter set to 1 (indicating no multiplicative effect 
of time on the hazard rate). Importantly, both distributions fulfil 
the proportional hazards assumption of the log-rank test.
Our first aim was to evaluate whether ALS survival patterns 
are best modelled by a constant (ie, exponential) or increasing 
(ie, Weibull) hazard rate. A likelihood ratio test was used to 
compare an exponential (Weibull shape 1) with the best fitting 
:HLEXOOPRGHO :HLEXOO VKDSH0RGHOVZHUH ILWWHG LQHDFK
trial dataset individually. Subsequently, we pooled the log-trans-
formed Weibull shape parameters using a fixed effects meta-anal-
ysis.19 In none of the trials there was an effect of treatment, 
we therefore did not distinguish between patients on active or 
placebo treatment. Nevertheless, we performed one sensitivity 
analysis using only the placebo arms of each cohort to evaluate 
the consistency of our results.
Our second aim was to evaluate how assuming a constant 
:HLEXOO VKDSH  RU LQFUHDVLQJ :HLEXOO VKDSH KD]DUG
rate at the design stage affects sample size calculations. The 
required number of events to detect a given effect size (ie, HR) 
was estimated with the formulae provided by Schoenfeld and 
Freedman.25 26 The probability of an event for a constant hazard 
rate was calculated using the framework described in Abel et 
al;17 we used a modified framework to allow accelerating hazard 
rates.27 All sample size calculations assumed a 1:1 randomisa-
tion ratio, uniform accrual period (ie, constant recruitment rate) 
and no loss-to-follow-up other than death or administrative 
censoring. To validate sample size estimations, we simulated 
clinical trial survival data based on both the exponential and 
Weibull distributions, as described previously.14 15 All statistical 
analyses and simulations were programmed in the R package 
Shiny (V.1.1.0, Chang et al, 2018); the source documentation 
can be found at http:// reactive. tricals. org.
RESULTS
In total, we identified 14 trials with mortality as (co-)primary 
endpoint; one trial was excluded due to incomplete reporting 
(vitamin E, 2005).28 Trials varied widely in predicted hazard 
rates, definitions of survival, follow-up durations and hypothe-
sised treatment effects (table 1). The median expected treatment 
effect (ie, HR) was 0.56 (range 0.330.66). All trials assumed a 
constant (ie, exponential) hazard rate, with a mean of 3.0 (range 
0.95.1) events per 100 person-months and a hypothesised 
survival probability in the placebo arm of 58% (range 40%85%) 
after 18 months. On average, the survival probability was under-
estimated with an absolute difference of 5.8% (95% CI 1.0% to 
10.6%), resulting in a mean overestimation of the hazard rate of 
18.9% (95% CI 3.4% to 34.5%, p=0.021). Five trials (38.5%) 
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Table 1 Design characteristics and assumptions of placebo-controlled trials in ALS with mortality endpoints
Design characteristics Assumed survival Observed survival
Treatment (year) No. patients Event Follow-up Treatment effect
(HR)
Survival (%)
(at month)
Hazard rate Survival (%) Hazard rate
Creatine (2003) 175 D, T, N 16 0.44 60 (16) 3.2 53.5 3.9
Xaliproden I (2004) 867 D, T, N 18 0.62 50 (18) 3.9 53.8 3.4
Xaliproden II (2004) 1210 D, T, N 18 0.66 57 (18) 3.1 62.3 2.6
Pentoxifylline (2006) 400 D 18 0.65 40 (18) 5.1 59.7 2.9
Valproic acid (2009) 163 D, T, N 16 0.56 60 (16) 3.2 75.1 1.8
Lithium (2012) 133 D, T, N 16 0.56 60 (16) 3.2 66.5 2.5
Pioglitazone (2012) 219 D ≥18 0.49 60 (18) 2.8 69.6 2.0
Dexpramipexole (2013) 942 D, T, N 12–18 0.63 80 (12) 1.9 80.7 1.8
Lithium (2013) 214 D 18 0.45 65 (18) 2.4 59.4 2.9
Ceftriaxone (2014) 513 D, T, N ≥12 0.66 75 (12) 2.4 74.6 2.4
Olesoxime (2014) 512 D, T, N 18 0.63 62 (18) 2.7 67.2 2.2
Erythropoietin (2015) 208 D, T, N 12 0.33 58 (12) 4.5 74.1 2.5
Ozanezumab (2017) 303 D 11 0.49 90 (11) 0.9 96.1 0.4
Follow-up time is given in months. Number of patients is for the total sample size. Hazard rates are given in number of events per 100 person-months.
ALS, amyotrophic lateral sclerosis; D, death; N, non-invasive ventilation; T, tracheostomy.
overestimated the hazard rate by more than 25%. Only two 
trials (Ceftriaxone 2014 and Pioglitazone 2012) considered the 
accrual period when determining the sample size.29 30
Hazard rates in ALS clinical trials
Using clinical trial data from five independent cohorts (n=4991), 
we evaluated the assumption of a constant hazard rate in ALS 
(figure 1). In all cohorts, we found evidence for an increasing 
mean hazard rate over time (pooled Weibull shape parameter of 
2.03, 95% CI 1.93 to 2.15, p<0.001, Cochrans Q test p=0.12). 
This result was similar when analysing only patients allocated to 
placebo (2.22, 95% CI 2.05 to 2.40, p<0.001). For example, the 
mean hazard rate in PRO-ACT during month 03 was 0.3 deaths 
per 100 person-months, which increased to 2.7 deaths per 100 
person-months during month 1518. This finding has important 
consequences for the number of events: in a hypothetical trial of 
100 patients, with an 80% survival after 12 months, a constant 
rate predicts 11, 20 and 28 deaths after 6, 12 and 18 months, 
whereas an increasing hazard rate (Weibull shape parameter 
of 2) predicts 5, 20 and 39 deaths, respectively. Although the 
number of events at 12 months is identical, before and after this 
time point, the constant hazard assumption severely overesti-
mates and underestimates the event probability.
Spending time wisely: importance of accrual
The majority of the ALS trials followed patients for a fixed time 
period. However, as patients are not enrolled simultaneously, 
the actual trial duration (from start to last follow-up) is the 
follow-up duration plus the accrual (ie, enrolment) period. We 
illustrate this process for 15 EMPOWER patients in figure 2A. 
An option might be to extend follow-up for those patients 
enrolled first, until the last patient has completed follow-up (ie, 
variable follow-up, figure 2B). Consequently, patients remain 
longer in the trial, generate more events and, consequently, the 
required sample size could be reduced. Importantly, the total 
trial duration is identical in both settings. In figure 2C, we show 
that assuming a constant hazard rate, using the observed 12 
month survival in EMPOWER, severely overestimates survival 
for this extended follow-up period and underestimates the total 
number of events during the entire trial (figure 2D).
Effects on historical trial designs
Finally, we evaluated how increasing hazards and accrual affect 
ALS trials in terms of sample size, trial duration, costs and drug 
exposure time. We redesigned each trial from table 1 according 
to the observed accrual period and its original hypotheses under 
(1) constant and increasing hazard rates and (2) with and without 
accrual; power, alpha and the treatment effect were fixed. The 
results are given in figure 3. When accrual is not incorporated, 
both the constant and increasing rate provide identical sample 
sizes. However, when assuming the true survival pattern is accel-
erating (figure 1), the constant hazard assumption underesti-
mates drug product usage by up to 11.1% (mean 4.7%; 95% CI 
3.1 to 6.3, p<0.001) and follow-up costs by up to 10.5% (mean 
4.8%; 95% CI 3.3 to 6.3, p<0.001). Incorporating accrual 
time and assuming an increasing hazard rate at the design stage 
reduced sample size, on average, by 33.2% (95% CI 27.9 to 
39.4, p<0.001), trial duration by 17.4% (95% CI 11.6 to 23.3, 
p<0.001), drug use by 14.3% (95% CI 9.6 to 19.0, p<0.001) 
and follow-up costs by 21.2% (95% CI 15.6 to 26.8, p<0.001) 
compared with the classical design (constant hazard rate without 
accrual).
Implementation tool for future trials
In order to improve the implementation of increasing hazard 
rates and accrual into trial designs for future trials, we developed 
an open-access platform for time-to-event sample size calcula-
tions based on the presented methodology (TRICALS-Reactive; 
http:// reactive. tricals. org). The platform provides estimates for 
survival patterns, acceleration rates and sample sizes. Estimates 
are based on the PRO-ACT database. Online supplementary 
eTable 1 provides a comparison of the performance of the plat-
form as compared with classical methods (modified to allow 
Weibull distributions).27 As described previously,17 Freedman is 
slightly conservative, whereas Schoenfeld is more liberal. The 
platform performs similarly to Schoenfeld and closely matches 
its target power.
DISCUSSION
In this study, we evaluated key assumptions underlying time-to-
event designs for ALS clinical trials. We found consistent evidence 
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Figure 1 constant versus increasing hazard rates in ALs clinical trials. Two models were itted with either an exponential or Weibull distribution. The 
exponential model assumes a constant hazard rate over time (or Weibull shape parameter p of 1). Within each cohort, we determined whether the Weibull 
shape parameter p was different from 1. Results across cohorts are pooled by a ixed effects meta-analysis (lower right panel). ALs, amyotrophic lateral 
sclerosis; PRO-AcT, Pooled Resource Open-Access ALs clinical Trials; VPA, Valproic acid study; EMPOWER, acronym of the dexpramipexole study; LicALs, 
acronym of the United Kingdom Lithium study.
for increasing hazard rates over time, which has important 
consequences for the design and planning of future clinical trials. 
Additionally, our results reveal a clear efficiency gain when the 
accrual period is incorporated into the design: extending the 
follow-up period for participants enrolled early in the trial 
considerably reduces sample sizes and, consequently, costs. As 
funds and resources for rare neurological disorders are limited, 
optimising their use is vital for efficient drug development. In 
order to mediate the implementation of our results, we devel-
oped an open-source, data-driven online platform that reduces 
the risk of mis-specification and facilitates sample size calcula-
tions for increasing hazards. The platform could be extended 
and applied in other disorders with time-to-event endpoints.
The need for sample size calculations is based on the ethical 
imperative to minimise the number of patients exposed to 
harmful experiments or inferior treatments,31 yet the number of 
enrolled patients needs to be sufficient to avoid falling short of 
demonstrating efficacy, or worse, generating false conclusions. 
Sample size calculations are, therefore, a balancing act, where 
inaccurate estimation can unnecessarily put patients at risk 
or lead to a large waste of resources. Sample size calculations 
require the investigator to make several assumptions, which are 
well known to be arbitrary with a high risk of mis-specifica-
tion.32 33 Our results reveal a systematic mis-specification among 
ALS clinical trials with an 18.9% overestimation of the hazard 
rate. Moreover, we found that, despite all trials being based on 
the same primary endpoint, trials varied widely in their defini-
tion of the event, effect size, follow-up duration and assumed 
survival probabilities. This variability affects sample size esti-
mation and underscores the current lack of guidance in trial 
design for ALS.19 Improving the standardisation of trial design 
could improve the interpretation of trial results, facilitate cross-
trial comparisons and potentially harmonise the reporting of 
trial results.34 Our developed framework provides, along with 
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Figure 2 Trial duration, accrual and number of events in EMPOWER. (A) classical trial design with ixed follow-up (here 12 months) for 15 EMPOWER 
patients. As patients are not all recruited at the same time, the total trial duration is the sum of the follow-up and accrual periods. (B) Extending follow-up 
until the last enrolled patient completed the 12 month follow-up increases the number of events and increases power. (c) Using the observed 12-month 
survival in EMPOWER, a constant (exponential) assumption underestimates survival before 12 months and subsequently overestimates survival. (D) Based 
on the EMPOWER data (n=942), we determined for each time point the expected number of events under the exponential and Weibull models. The black 
crosses are the observed events over time.
data-driven assumptions, a platform for the development and 
implementation of future guidelines for ALS clinical trials.
The systematic mis-specification in ALS clinical trials is 
partially the result of erroneously assuming a constant hazard 
rate during follow-up. Trial participants are a selected subpop-
ulation,19 35 from which far-progressed patients in the end stage 
of ALS are excluded. Consequently, the event probability during 
a trial is initially low and increases over time. This acceleration 
factor was confirmed in our meta-analysis (figure 1). This has 
important consequences for sample size calculations and cost 
estimation and also for the planning of milestones. The Pioglita-
zone trial, for example, planned one interim analysis after 50% 
of the required number of events. Assuming a constant hazard, 
the interim analysis was planned after 12.3 months. After 12 
months, however, the authors report that the number of events 
was unexpectedly low (~38% of required) and the interim anal-
ysis was abandoned.30 If the trial had assumed an increasing 
hazard (eg, Weibull shape 2), the interim analysis would have 
been conducted 4.5 months later at 16.7 months.14 At that time, 
the authors would probably have reached their 50% target and 
might have stopped the trial earlier for reasons of futility, poten-
tially reducing the loss of resources.
The efficiency of ALS trials with time-to-event endpoints could 
be further improved by including accrual at the design stage. 
However, early-enrolled participants would remain in the trial 
for a considerable amount of time, which may increase dropout 
rates. The feasibility of a prolonged follow-up period in ALS 
has been shown before by the Ceftriaxone trial,29 and recently 
by a trial with methylcobalamin,36 where some patients partic-
ipated for over 4 years. Registry data from large longitudinal 
population-based cohorts could additionally provide insight into 
follow-up patterns, as patients are often monitored from diag-
nosis until death. Moreover, extending follow-up could improve 
a trials generalisability to long-term treatments that patients 
with ALS will probably require. Nevertheless, incorporating 
accrual at the design stage does require accurate prior assump-
tions and this further underscores the necessity of (online) tools 
such as those presented here. Our study did not evaluate the 
accrual and dropout patterns in ALS trials, and incorporating 
separate models for accrual and dropout rates may further opti-
mise their design and planning. As an alternative, a trial may 
continue to run until the required number of events is reached. 
This would make the trial duration (from first enrolment to last 
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Figure 3 Effect of accrual and increasing hazards on historical trial designs. For each trial speciied in table 1, we re-estimated the sample size according 
to the observed accrual period and the original design assumptions (x-axis). We provide in the left column barcharts the estimated sample size, total trial 
duration, product usage and follow-up costs and in the right column barcharts their respective relative increases as compared with the classical trial design 
(ie, constant hazard rate, without incorporating accrual). We used the formula of schoenfeld to determine the number of events. Trial designs for accelerated 
(ie, increasing) hazards were based on a Weibull shape of 2.
follow-up visit) uncertain, but prevent losses in efficiency due to 
inaccurate assumptions of accrual, dropout and/or hazard rates.
As a final note, survival patterns in clinical trials may be 
affected by eligibility criteria, or geographical differences in care 
or infrastructure, which may affect sample size.19 To illustrate, if 
we use the default settings in our tool, the estimated sample size 
is 412 patients. When selecting patients between 60 and 70 years 
old, symptom duration of 1218 months and %predicted lung 
function of 60%90%, the sample size is reduced to 258. In this 
case, the difference in sample size is primarily driven by a differ-
ence in death rates (ie, 18 month survival of 71.2% vs 49.7%, 
respectively). In addition, survival patterns in future trials may 
alter due to improved diagnostic strategies or the use of combina-
tion therapies. Although our current tool has the ability to study 
the effect of eligibility criteria on sample size, more detailed data 
(eg, genotype or prediction-based information) may be required 
to accommodate all future settings. Moreover, the development 
of similar modelling techniques for other efficacy endpoints such 
as the ALS functional rating scale or the joint modelling frame-
work may further optimise the design of clinical trials.37
In conclusion, resources for rare incurable disorders such as 
ALS are limited, and optimising their use is vital to increase 
the efficiency of drug development. Large reductions in sample 
size, duration and costs of ALS clinical trials with time-to-event 
endpoints could be achieved by implementing parametrical 
models that incorporate prior knowledge of the survival patterns 
and incorporating accrual at the design stage. We provide an 
open-source platform that helps investigators make more accu-
rate sample size calculations and optimise the use of their avail-
able resources.
Author affiliations
1Department of Neurology, Brain center Rudolf Magnus, University Medical centre 
Utrecht, Utrecht, The Netherlands
by copyright.
 o
n
 20 August 2019 at Sheffield Uni Consortia. Protected
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-320998 on 10 July 2019. Downloaded from 
7van Eijk RPA, et al. J Neurol Neurosurg Psychiatry 2019;0:1–7. doi:10.1136/jnnp-2019-320998
Neuromuscular
2Biostatistics & Research support, Julius centre for health sciences and Primary 
care, Utrecht, The Netherlands
3Department of Neurology Research and Early clinical Development, Biogen Inc, 
cambridge, Massachusetts, UsA
4shefield Institute for Translational Neuroscience, University of shefield, shefield, 
UK
5Department of clinical Neuroscience, Trafford centre for Biomedical Research, 
Brighton and sussex Medical school, Brighton, UK
6Department of Basic and clinical Neuroscience, Maurice Wohl clinical Neuroscience 
Institute, King’s college London, London, UK
Contributors RPAvE, sN: study concept, design, analysis, interpretation of data and 
drafting manuscript. KcBR, MJcE: study concept, design, analysis and interpretation 
of data. BMM: design and critical revision of manuscript for intellectual content. TAF, 
PJs, PNL, AA-c: acquisition of data, critical revision of manuscript for intellectual 
content. LhvdB: study supervision and critical revision of manuscript for intellectual 
content.
Funding This study was funded by the Netherlands ALs Foundation (Project 
TRIcALs-Reactive).
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available in a public, open access 
repository. All data relevant to the study are included in the article or uploaded as 
supplementary information.
Open access This is an open access article distributed in accordance with the 
creative commons Attribution Non commercial (cc BY-Nc 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. see: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
REFERENCES
 1 Berry JD, cudkowicz ME. New considerations in the design of clinical trials for 
amyotrophic lateral sclerosis. Clin Investig 2011;1:1375–89.
 2 Mitsumoto h, Brooks BR, silani V. clinical trials in amyotrophic lateral sclerosis: 
why so many negative trials and how can trials be improved? Lancet Neurol 
2014;13:1127–38.
 3 chio A, canosa A, Gallo s, et al. ALs clinical trials: do enrolled patients accurately 
represent the ALs population? Neurology 2011;77:1432–7.
 4 Miller RG, Moore Dh. ALs trial design: expectation and reality. Amyotroph Lateral 
Scler Other Motor Neuron Disord 2004;5 suppl 1:52–4.
 5 van Es MA, hardiman O, chio A, et al. Amyotrophic lateral sclerosis. The Lancet 
2017;390:2084–98.
 6 Knibb JA, Keren N, Kulka A, et al. A clinical tool for predicting survival in ALs. J Neurol 
Neurosurg Psychiatry 2016;87:1361–7.
 7 shefner JM. Designing clinical trials in amyotrophic lateral sclerosis. Phys Med Rehabil 
Clin N Am 2008;19:495–508.
 8 Food Drug Administration center for Drugs Evaluation Research. Guidance for 
Industry: Amyotrophic Lateral sclerosis: Developing Drugs for Treatment, 2018. 
Available: https://www. fda. gov/ downloads/ Drugs/ Guid ance comp lian ceRe gula tory Info 
rmation/ Guidances/ UcM596718. pdf [Accessed 1 May 2019].
 9 European Medicines Agency. Guideline on clinical investigation of medicinal products 
for the treatment of amyotrophic lateral sclerosis, 2016. Available: https://www. ema. 
europa. eu/ documents/ scientiic- guideline/ guideline- clinical- investigation- medicinal- 
products- treatment- amyotrophic- lateral- sclerosis_ en. pdf [Accessed 1 May 2019].
 10 Edaravone Writing Group. safety and eficacy of edaravone in well deined patients 
with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled 
trial. Lancet Neurol 2017;16:505–12.
 11 van Eekelen R, de hoop E, van der Tweel I. simultaneous sequential monitoring of 
eficacy and safety led to masking of effects. J Clin Epidemiol 2016;76:155–65.
 12 hardiman O, van den Berg Lh. Edaravone: a new treatment for ALs on the horizon? 
Lancet Neurol 2017;16:490–1.
 13 Al-chalabi A, Andersen PM, chandran s, et al. ENcALs statement on edaravone. 
Amyotroph Lateral Scler Frontotemporal Degener 2017;2017:471–4.
 14 van Eijk RPA, Nikolakopoulos s, Ferguson TA, et al. Increasing the eficiency of clinical 
trials in neurodegenerative disorders using group sequential trial designs. J Clin 
Epidemiol 2018;98:80–8.
 15 van Eijk RP, Eijkemans MJ, Rizopoulos D, et al. comparing methods to combine 
functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin 
Epidemiol 2018;10:333–41.
 16 schoenfeld DA. sample-size formula for the proportional-hazards regression model. 
Biometrics 1983;39:499–503.
 17 Abel UR, Jensen K, Karapanagiotou-schenkel I, et al. some issues of sample size 
calculation for Time-to-Event endpoints using the Freedman and schoenfeld formulas. 
J Biopharm Stat 2015;25:1285–311.
 18 Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival 
with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and 
stratiication. Biometrics 1986;42:507–19.
 19 van Eijk RPA, Westeneng h-J, Nikolakopoulos s, et al. Reining eligibility criteria for 
amyotrophic lateral sclerosis clinical trials. Neurology 2019;92:e451–60.
 20 Atassi N, Berry J, shui A, et al. The PRO-AcT database: design, initial analyses, and 
predictive features. Neurology 2014;83:1719–25.
 21 Groeneveld GJ, Veldink Jh, van der Tweel I, et al. A randomized sequential trial of 
creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437–45.
 22 Piepers s, Veldink Jh, de Jong sW, et al. Randomized sequential trial of valproic acid 
in amyotrophic lateral sclerosis. Ann Neurol 2009;66:227–34.
 23 Morrison KE, Dhariwal s, hornabrook R, et al. Lithium in patients with amyotrophic 
lateral sclerosis (LicALs): a phase 3 multicentre, randomised, double-blind, placebo-
controlled trial. Lancet Neurol 2013;12:339–45.
 24 cudkowicz ME, van den Berg Lh, shefner JM, et al. Dexpramipexole versus placebo 
for patients with amyotrophic lateral sclerosis (empower): a randomised, double-blind, 
phase 3 trial. Lancet Neurol 2013;12:1059–67.
 25 Freedman Ls. Tables of the number of patients required in clinical trials using the 
logrank test. Stat Med 1982;1:121–9.
 26 schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed 
for a clinical trial with survival as an endpoint. Biometrics 1982;38:163–70.
 27 Wu JR. Power and sample size for randomized phase III survival trials under the 
Weibull model. J Biopharm Stat 2015;25:16–28.
 28 Graf M, Ecker D, horowski R, et al. high dose vitamin E therapy in amyotrophic lateral 
sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind 
study. J Neural Transm 2005;112:649–60.
 29 cudkowicz ME, Titus s, Kearney M, et al. safety and eficacy of ceftriaxone for 
amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-
controlled trial. Lancet Neurol 2014;13:1083–91.
 30 Dupuis L, Dengler R, heneka MT, et al. A randomized, double blind, placebo-controlled 
trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS 
One 2012;7:e37885.
 31 cesana BM, Antonelli P. sample size calculations in clinical research should also be 
based on ethical principles. Trials 2016;17.
 32 Nikolakopoulos s, Roes KcB, van der Lee Jh, et al. sample size calculations in 
pediatric clinical trials conducted in an IcU: a systematic review. Trials 2014;15.
 33 Tavernier E, Giraudeau B. sample size calculation: inaccurate a priori assumptions for 
nuisance parameters can greatly affect the power of a randomized controlled trial. 
PLoS One 2015;10:e0132578.
 34 Gourgou-Bourgade s, cameron D, Poortmans P, et al. Guidelines for time-to-event 
end point deinitions in breast cancer trials: results of the DATEcAN initiative 
(Deinition for the Assessment of Time-to-event Endpoints in cANcer trials)†. Ann 
Oncol 2015;26:873–9.
 35 hardiman O, Al-chalabi A, Brayne c, et al. The changing picture of amyotrophic 
lateral sclerosis: lessons from European Registers. J Neurol Neurosurg Psychiatry 
2017;88:557–63.
 36 Kaji R, Imai T, Iwasaki Y, et al. Ultra-high-dose methylcobalamin in amyotrophic lateral 
sclerosis: a long-term phase II/III randomised controlled study. J Neurol Neurosurg 
Psychiatry 2019;90:451–7.
 37 van Eijk RPA, Rooney J, hardiman O, et al. Two heads are better than one: beneits of 
joint Models for ALs trials. J Neurol Neurosurg Psychiatry 2019.
by copyright.
 o
n
 20 August 2019 at Sheffield Uni Consortia. Protected
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-320998 on 10 July 2019. Downloaded from 
